Advertisement


Xuesong Han, PhD, on Early-Stage Diagnosis and the Affordable Care Act: An Epidemiologic Study

2017 ASCO Annual Meeting

Advertisement

Xuesong Han, PhD, of the American Cancer Society, discusses the Affordable Care Act and her study findings showing how implementation of the law is associated with a shift to early-stage diagnosis for all screenable cancers except prostate cancer (likely due to Task Force recommendations against routine screening). (Abstract 6521)



Related Videos

Colorectal Cancer

Temidayo Fadelu, MD, on Colon Cancer: Results From the CALGB 89803 Trial

Temidayo Fadelu, MD, of Dana-Farber Cancer Institute, discusses study findings on nut consumption and survival in stage III colon cancer patients. Higher consumption of nuts may be associated with significantly reduced cancer recurrence and death in this group. (Abstract 3517)

Gynecologic Cancers

Ronald J. Buckanovich, MD, PhD, on Ovarian Cancer: Expert Perspective on the ICON6 Trial

Ronald J. Buckanovich, MD, PhD, of the University of Michigan, discusses study findings on chemotherapy and cediranib in relapsed ovarian cancer. (Abstract 5506)

Supportive Care

Jane McNeil Beith, MD, PhD, on Reducing Fear in Cancer Survivors

Jane McNeil Beith, MD, PhD, of Chris O’Brien Lifehouse, discusses long-term study results on a psychological intervention, called “Conquer Fear,” designed to reduce clinical levels of fear of cancer recurrence in breast, colorectal, and melanoma cancer survivors. (Abstract LBA10000)

Breast Cancer
Survivorship

Matteo Lambertini, MD, on Pregnancy in Breast Cancer Patients: Results From a Multicenter Study

Matteo Lambertini, MD, of the Institut Jules Bordet, discusses a long-term follow-up analysis of the safety of pregnancy in patients with a history of estrogen receptor–positive breast cancer. (Abstract LBA10066)

Lung Cancer

Arnaud Scherpereel, MD, PhD, on Mesothelioma: Results From the IFCT-1501 MAPS2 Trial (French Language Version)

Arnaud Scherpereel, MD, PhD, of the University Hospital of Lille, discusses in French phase II study findings on second- or third-line nivolumab vs nivolumab plus ipilimumab in malignant pleural mesothelioma patients. (Abstract LBA8507)

Advertisement

Advertisement




Advertisement